What are my alternatives to knee replacement?
Compare nonsurgical knee arthritis care, injection choices, and selected surgical alternatives—with evidence, limits, and questions for your clinician.
Read the guide ↗Medically reviewed by Charles A. DeCook, MD ·
← All optionsLearn about the evidence
Amniotic products & exosomes
Unapproved joint injections. No buy button.
Who might it suit?
For: Understanding amniotic, umbilical, Wharton’s jelly, and exosome claims.
Not for: Commercial OA treatment on this platform.
Limits and important cautions
Do not transfer results from one study preparation to another vial. Product identity, contamination, immune effects, and regulatory status need scrutiny.
What happens, how long, and what could it cost?
- What happens
- Ask the clinician to explain the exact product or procedure and confirm the diagnosis before treatment.
- When might I notice a change?
- A reliable personal timeline cannot be predicted from the evidence reviewed here. Agree on a review date before starting.
- How long might benefit last?
- Benefit and durability depend on the exact intervention and population. The evidence section below explains what is known.
- Repeat treatment
- Agree on a review date and criteria for continuing, changing, or stopping.
- Activity and recovery
- Ask who provides follow-up, what symptoms need urgent attention, and what restrictions apply to you.
- Ask for a complete estimate
- Consultation, exact product or procedure, any tests, follow-up, and repeat treatment.
Use this as a consultation guide. A timeline is not a guarantee; the evidence and FDA sections below remain part of the decision.
THE EVIDENCE IN CONTEXT
Investigational evidence; no class-wide efficacy conclusion
Read the 2 selected references
- Placental-cell extracellular vesicles in knee OA ↗
A specific investigational preparation in a small bilateral-knee study. It cannot validate commercial exosome or birth-tissue products as a class.
- FDA: regenerative medicine products ↗
Addresses unapproved orthopedic claims and safety concerns. Regulatory status is separate from the size of any clinical effect.
FDA status
Not approved for OA injectionsNot approved for OA injection; FDA warns patients about unapproved regenerative products.
Site summary of FDA information · reviewed September 19, 2026. Refer to current product labeling. This is not an FDA endorsement of this site.What do professional guidelines say?
ACR: No endorsement for these OA products.
Will Medicare cover it?
No routine OA coverage.